The Biotech Growth Trust PLC



Portfolio Manager





@BiotechGT


Information as at 30 November 2019

Investment Objective and Benchmark Index

The Biotech Growth Trust PLC seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



Benchmark: NASDAQ Biotechnology Index (sterling adjusted) +42.7% Net Asset Value per share (total return) +36.3% Share Price (total return) +19.9% Source: Morningstar, Index - Bloomberg.

Commentary

In November, the NAV per share was up 19.1%, the share price was up 17.9% and the benchmark NASDAQ Biotechnology Index (sterling adjusted) was up 11.5%.

Biotechnology continued its strong outperformance relative to the broader markets in November. Sentiment in biotechnology has dramatically improved since September, driven in part by a number of high-premium M&A transactions in the space, including Novartis' \$9.7 bn acquisition of the Medicines Company. Sentiment has also improved due to several positive clinical trial readouts recently that have led to outsized positive stock performance. An additional tailwind for healthcare has been the changing dynamics of the U.S. Democratic Presidential primary race. Candidates with more moderate stances on healthcare and drug price reform, including former Vice President Joe Biden and Mayor Pete Buttigieg, have seen their polling numbers improve recently relative to more progressive candidates like Senators Elizabeth Warren and Bernie Sanders, both of whom have proposed major healthcare reform by stating that she would not attempt to implement Medicare for All immediately but would do so in a stepwise fashion over a few years. We continue to see the current healthcare reform proposals by the more progressive Democratic candidates as unlikely to be enacted.

CRISPR Therapeutics, Vertex and Sarepta were the top positive contributors to performance during the month. Shares in both CRISPR Therapeutics and its partner Vertex were strong after the companies released initial data from a Phase 1/2 trial of CTX001, a CRISPR-based gene editing candidate, for sickle cell disease and beta-thalassemia. The data was the first CRISPR gene editing data produced in humans and showed strong clinical benefit in treated patients, albeit in a small 2-patient cohort. We view this data as strongly de-risking for gene editing approaches, including additional programs in the CRISPR and Vertex partnership. Shares in Sarepta outperformed as a key competing treatment in Duchenne muscular dystrophy (DMD) gene therapy, Solid Biosciences' SGT-001, was put on FDA clinical hold due to a severe adverse event in the clinical trial. We continue to view Sarepta's SRP-9001 as the best-in-class gene therapy candidate for DMD with compelling initial efficacy data and a potentially differentiated safety profile from its competitors.

Curis, Ultragenyx and Hansoh Pharmaceutical were the largest negative contributors to performance during the month. Curis shares were weak as the company discontinued development of CA-170 in mesothelioma after disappointing initial clinical data. We continue to see value in CA-4948 as a potentially differentiated candidate in hematologic malignancies. Ultragenyx shares declined as the company reported Crysvita revenues slightly below consensus, and investors questioned the reasons behind the company's amendments in the development strategy of DTX301, a gene therapy candidate for ornithine transcarbamylase (OTC) deficiency. Given the missteps in the company's gene therapy pipeline, we have exited the position. Shares in Hansoh Pharmaceutical were weak on the last day of the month due to the announcement of results for China's National Drug Reimbursement List, which revealed more significant price cuts for innovative drugs than investors were anticipating. While drug pricing in China needs to be monitored, we continue to believe that the rise of innovative biotech companies in China represents an attractive long-term investment opportunity.

www.biotechqt.com

Biographies

Geoffrey C. Hsu, CFA, is a General Partner of OrbiMed, having joined in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as an analyst in the healthcare investment banking group at Lehman Brothers. Geoff received his A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School.

Richard D. Klemm, Ph.D., CFA, is a Public Equity Partner at OrbiMed focused on biotechnology companies. He completed a Ph.D. from the Massachusetts Institute of Technology in molecular biology in 2000. Richard has published scientific articles in the fields of DNA replication and transcription. He received a B.A. from the University of California, Berkeley in 1994 with majors in molecular and cell biology and economics.

Portfolio Manager Profile

Portfolio management services are provided by OrbiMed Capital LLC (OrbiMed). OrbiMed is owned by six principals, including Geoff Hsu. The U.S.-based firm employs over 80 experienced investment professionals who between them have extensive scientific, medical, financial and operational expertise. They employ a bottom-up stock selection process driven by intensive proprietary research, which involves company visits and developing an understanding of commercial prospects and development programmes for individual drugs. The firm covers some 600 international pharmaceutical and biotechnology companies, two thirds of which are actively researched. OrbiMed is registered as an investment adviser under the U.S. Securities and Exchange Commission (SEC). SEC registration does not imply a certain level of skill or training.

Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. It will not invest more than 10% of the value of its gross assets in direct unquoted investments at the time of acquisition. This limit does not include any investment in private equity funds managed by the Portfolio Manager or any affiliates of such entity. Up to US\$15m, after the deduction of proceeds of disposal and other returns of capital, may be invested in private equity funds managed by OrbiMed or an affiliate. The Company's borrowing policy is that borrowings will not exceed 20% of the Company's net assets. The Company may be unable to invest directly in certain countries. In these circumstances, the Company may gain exposure to companies in such countries by investing indirectly through swaps. Where the Company invests in swaps, exposure to underlying assets will not exceed 5% of the gross assets of the Company at the time of entering into the contract.

Discount Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled.

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers ("IFAs") to retail private investors. The shares are excluded from the Financial Conduct Authority's ("FCA's") restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.

The Biotech Growth Trust PLC

10 Largest Holdings at 30 November 2019 (% of total investments)

Name	Total
Vertex Pharmaceuticals	9.9
Amgen	5.2
Neurocrine Biosciences	5.2
Mirati Therapeutics	5.0
CRISPR Therapeutics	4.9
Biogen	4.6
Sarepta Therapeutics	4.2
Gilead Sciences	4.0
Alexion Pharmaceuticals	3.8
MeiraGTx	3.5
Total	50.3

Geographical Breakdown as at 30 November 2019 (%)

Total	100.0%
*Unquoted	0.7%
United Kingdom	1.3%
Other	6.1%
Continental Europe	7.4%
North America	84.5%

* No more than 10% of gross assets will be invested in direct unquoted investments at the time of acquisition. The Company may also invest or commit for investment a maximum of US15m, after the deduction of proceeds of disposal and other returns of capital, in private equity funds managed by the Company's Portfolio Manager or an affiliate thereof.

Source: All portfolio information sourced from Frostrow Capital LLP

Discrete Performance – Calendar Years (%)

Percentage Growth 12 Month Return	2014	2015	2016	2017	2018	YTD
NAV	43.1	15.6	-7.6	9.9	-14.3	35.7
Share Price	44.9	9.1	-4.7	12.1	-19.9	33.0
Index	42.6	17.8	-6.5	10.5	-3.8	21.6

Standardised Discrete Performance (%)

Percentage Growth 12 Month Return	Nov 14- Nov 15	Nov 15- Nov 16	Nov 16- Nov 17	Nov 17- Nov 18	Nov 18- Nov 19
NAV	12.6	-3.7	6.9	-0.7	18.3
Share Price	1.8	3.6	5.1	-7.3	16.6
Index	14.3	-1.5	6.8	9.8	8.0

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed.

Source: NAV (total return; fully diluted) & Share Price (total return) - Morningstar. Index - Bloomberg.

Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.biotechgt.com. The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are premium listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held will be held in 2020).

www.biotechgt.com

Fast Facts	As at 30 November 2019
Launch Date	June 1997
AIC Sector	Biotechnology & Healthcare
Date of App	ointment of OrbiMed 19 May 2005
Annual Management	Fee (payable by the Company)
0.65% of net	assets plus 0.30% of market cap.
	<u>plus</u> £60,000
Performance fee	See Annual Report for details
Ongoing charges*	1.1%
Continuation Vote	At AGM in 2020; every 5 years
Year / Half Year	31 March / 30 September
Capital Structure	43,851,887 Ordinary Shares
•	of 25p

Trust Characteristics

Number of Holdings	49
Total Net Assets (£m)	£407.1m
Market Capitalisation	
(£m)	£369.2m
Dividend Policy	It is not anticipated that the Company will pay a dividend
Gearing (AIC basis)	3.7%
Leverage**	
Gross & Commitment	103.7%
Share Price (p)	842.00
NAV (p)	928.43
(Discount) / Premium	(9.3%)
*Calculated at the financial year er other operating expenses, excludes **The Board has set the leverage li Commitment basis at 130% of the G	imit for both the Gross and the

Codes

Sedol	0038551
ISIN	GB0000385517
Legal Entity Identifier	549300Z41EP32MI2DN29
(LEI)	
Global Intermediary	
Identification Number	U1MQ70.99999.SL.826
(GIIN)	
Bloomberg	BIOG LN
EPIC	BIOG

How to Contact Us

Frostrow Capital LLP

25 Southampton Buildings, London, WC2A 1AL Tel.: 0203 0084910 Fax: 0203 0438889 Website: .www.frostrow.com

Email: info@frostrow.com Twitter: @BiotechGT

